| HOME >> BIOLOGY >> TECHNOLOGY |
4.2 5.1.1 Strategic Competitor Assessment 35
4.3 Product Profiles for the Major Marketed Products in the Influenza Vaccines Market 36
4.3.1 Fluarix 36
4.3.2 FluLaval 37
4.3.3 Flumist 38
4.3.4 Fluvirin 39
4.3.5 Fluzone 39
4.4 Key Takeaway 40
5 Influenza Vaccines - Pipeline Assessment 41
5.1 Overview 41
5.2 Strategic Pipeline Assessment 41
5.2.1 Influenza Vaccines Pipeline – Pipeline by Phases of Development 42
5.2.2 Influenza Vaccines – Regulatory Filed Products 42
5.2.3 Influenza Vaccines – Phase III Pipeline 43
5.2.4 Influenza Vaccines – Phase II Pipeline 43
5.2.5 Influenza Vaccines – Phase I Pipeline 44
5.2.6 Influenza Vaccines – Pre-Clinical Pipeline 45
5.2.7 Influenza Vaccines – Discovery Pipeline 46
5.2.8 Technology Trends Analytical Framework 47
5.3 Influenza Vaccines – Clinical Pipeline by Types of Vaccine 49
5.4 Influenza Vaccines – Promising Drugs Under Clinical Development 49
5.5 Molecule Profile for Promising Drugs Under Clinical Development 50
5.5.1 FluBlok 50
5.5.2 Flu Vaccine 51
5.5.3 MEDI 3250 51
5.5.4 A-04-01D Vaccine 52
5.5.5 H5N1 Pandemic Influenza Vaccine 52
5.5.6 Vepacel 52
5.6 Key Takeaway 52
6 Influenza Vaccines: Clinical Trials Mapping 53
6.1 Clinical Trials by Region/Country (The US, EU5 and Japan) 53
6.2 Clinical Trials by Phase 54
6.3 Clinical Trials by Trial Status 55
6.4 Prominent Sponsors 56
6.5 Top Companies Participating in Influenza Vaccines Clinical Trials 58
7 Influenza Vaccines: Strategic Assessment 59
7.1 Key Events Impacting the Future Market 59
7.2 Influenza Vaccines: Implications for Future Market Competition 60
8 Influenza Vaccines: Future Players 61
8.1 Introduction 61
8.2 Company Pr
'/>"/>
| SOURCE Reportlinker Copyright©2010 PR Newswire. All rights reserved |